Home › Funds › HOWLAND CAPITAL MANAGEMENT LLC › REGN

HOWLAND CAPITAL MANAGEMENT LLC position in REGN

REGENERON PHARMACEUTICALS · Health Care

HOWLAND CAPITAL MANAGEMENT LLC reported holding 37,174 shares of REGN (REGENERON PHARMACEUTICALS) in its Q2 2026 13F filing — a position valued at US$23.2M, representing 0.84% of its reported portfolio and ranking #35 among its reported holdings. HOWLAND CAPITAL MANAGEMENT LLC has disclosed REGN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)37.17K sh
Reported value held$23.18M
Portfolio Weight0.84%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How HOWLAND CAPITAL MANAGEMENT LLC's REGN position evolved

HOWLAND CAPITAL MANAGEMENT LLC first disclosed a stake in REGN in Q3 2023 at 1,341 shares (US$1.1M). The position peaked in Q1 2026 at 39,345 shares, worth US$30.4M. Across 12 filings, HOWLAND CAPITAL MANAGEMENT LLC increased the stake 6 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 37,174 shares valued at US$23.2M — a reduction of -2,171 shares quarter over quarter.. Notable position changes include a 1127% increase in Q4 2024 (shares fell 11% over the following quarter), a 73% increase in Q1 2025 (shares fell 17% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.34K $1.10M New
Q4 2023 1.33K $1.17M Reduce
Q1 2024 1.33K $1.28M Hold
Q2 2024 1.31K $1.38M Reduce
Q3 2024 1.26K $1.32M Reduce
Q4 2024 15.44K $11.00M Add
Q1 2025 26.69K $16.93M Add
Q2 2025 31.80K $16.69M Add
Q3 2025 35.69K $20.06M Add
Q4 2025 37.86K $29.22M Add
Q1 2026 39.34K $30.40M Add
Q2 2026 37.17K $23.18M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About REGN and 13F data

REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 31 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), LOOMIS SAYLES & CO L P (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding REGN

All REGN fund holders →

FAQ

How long has HOWLAND CAPITAL MANAGEMENT LLC held REGN?

HOWLAND CAPITAL MANAGEMENT LLC has disclosed REGN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is HOWLAND CAPITAL MANAGEMENT LLC's current position in REGN?

As of Q2 2026, HOWLAND CAPITAL MANAGEMENT LLC holds 37.17K shares of REGN (REGENERON PHARMACEUTICALS), valued at $23.18M, representing 0.84% of its reported portfolio and ranking #35.

Has HOWLAND CAPITAL MANAGEMENT LLC been buying or selling REGN?

In the latest 13F filing (Q2 2026), HOWLAND CAPITAL MANAGEMENT LLC reduced its position in REGN. The position peaked in Q1 2026 at 39.34K shares.

Which other funds hold REGN?

Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, LOOMIS SAYLES & CO L P, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.